ARTICLE | Targets & Mechanisms

Unexpected combinations

How two studies could change thinking on cancer combo strategies

January 25, 2018 11:34 PM UTC

Two studies are prompting a rethink of how combination therapies target cancer at both the level of individual cells, and across a patient population. The papers are pushing drug developers to parse data from preclinical and clinical combo studies with a new perspective, and could lead to new strategies for pairing compounds.

The rise of next-generation sequencing and other technologies has provided a wealth of molecular information about variability in cancer. But analyses of those data have not yet translated into a step change in drug development strategy, according to Daniel Peeper, an author on one of the studies and head of the Division of Molecular Oncology at the Netherlands Cancer Institute...